Arbor Investments Group takes 0.3% stake in Accession Therapeutics, an immuno-oncology firm
Published
Arbor Investments Group Limited entered the register with 5,665 A shares, giving it a 0.3% stake in Accession Therapeutics Limited. Overall shares rose from 1,208,588 to 1,625,009, while existing fund and corporate holders also increased their positions. The confirmation statement was filed on 16 December 2025, covering changes from 14 December 2024 to 14 December 2025.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| New shareholder | ARBOR INVESTMENTS GROUP LIMITED | 5,665 | — | A SHARES 5,665 |
Current shareholders (6)
| Shareholder | Total shares | Share classes |
|---|---|---|
| TURNMILL INVESTMENTS HOLDING LIMITED | 158,140 | ORDINARY 158,140 |
| IGLOBE CAPITAL VCC A/C IGPF IV (T21VC02073C-SF001) | 74,768 | A SHARES 5,000 ORDINARY 69,768 |
| ST CATHERINE'S COLLEGE IN THE UNIVERSITY OF OXFORD | 42,659 | A SHARES 4,532 ORDINARY 38,127 |
| BIRK VENTURE AS | 18,651 | ORDINARY 18,651 |
| RO INVEST AS | 18,651 | ORDINARY 18,651 |
| ARBOR INVESTMENTS GROUP LIMITED | 5,665 | A SHARES 5,665 |
Contact the editorial team at editorial@fundingspotter.com